Literature DB >> 6322488

Clinical experiences with pipecuronium bromide.

M Boros, J Szenohradszky, A Kertész, G Marosi, L Tutsek.   

Abstract

In two groups of patients the neuromuscular and circulatory effects of pipecuronium bromide (Arduan R), a new steroid type muscle relaxant were compared with those of pancuronium during balanced anaesthesia. Pipecuronium (n = 18) was found to be about 20% more potent than pancuronium (n = 20). The 95% blocking doses were: 0.059 mg kg-1 for pipecuronium and 0.075 mg kg-1 for pancuronium; these doses provided equal intubating conditions and relaxation. The onset, clinical relaxation time (clinical duration), recovery and the reversibility of the neuromuscular effects of the two agents in equipotent doses were similar. No cardiovascular or other side effects were observed with the use of pipecuronium.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6322488

Source DB:  PubMed          Journal:  Acta Chir Hung        ISSN: 0231-4614


  3 in total

Review 1.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

2.  Edrophonium priming alters the course of neuromuscular recovery from a pipecuronium neuromuscular blockade.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

3.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.